EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

Juan Wang, Wei Wang, Guanghui Xu, Shushang Liu, Longxing Jiao, Shu Wang, Chaosheng Peng, Yuxuan Ma, Xin Liu, Huade Huo, Haolin Li, Xiaohua Li, Jianjun Yang

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.70958 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT This single‐center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) therapy or nab‐paclitaxel, lobaplatin, and S‐1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single‐center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. Trial Registration ClinicalTrials.gov: NCT06169410

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →